Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (171-180 of 226) with videos related to

Pageof 23
Sort By:
Journal of Autoimmunity|July 10, 2022
GILZ regulates type I interferon release and sequesters STAT1Champa Nataraja, Jacqueline Flynn, Wendy Dankers, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Frontiers in Immunology|December 12, 2022
Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ)Wendy Dankers, Melissa Northcott, Taylah Bennett, et al.
Arthritis and Rheumatism|July 31, 2013
Macrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infectionLara J Herrero, Kuo-Ching Sheng, Peng Jian, et al.
Lancet (London, England)|May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trialEric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.
Lupus Science & Medicine|December 20, 2023
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signatureLaurent Arnaud, Richard Furie, Eric F Morand, et al.
Advances in Therapy|September 8, 2025
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus ErythematosusCristina Arriens, Eric F Morand, Anca D Askanase, et al.
Scientific Reports|October 30, 2019
Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosusSarah A Jones, Stuart Cantsilieris, Huapeng Fan, et al.
Nucleic Acids Research|June 12, 2012
A miR-19 regulon that controls NF-κB signalingMichael P Gantier, H James Stunden, Claire E McCoy, et al.
Pageof 23

Showing results (171-180 of 226) with videos related to

Sort By:
Pageof 23
Journal of Autoimmunity|July 10, 2022
GILZ regulates type I interferon release and sequesters STAT1Champa Nataraja, Jacqueline Flynn, Wendy Dankers, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Frontiers in Immunology|December 12, 2022
Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ)Wendy Dankers, Melissa Northcott, Taylah Bennett, et al.
Arthritis and Rheumatism|July 31, 2013
Macrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infectionLara J Herrero, Kuo-Ching Sheng, Peng Jian, et al.
Lancet (London, England)|May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trialEric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.
Lupus Science & Medicine|December 20, 2023
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signatureLaurent Arnaud, Richard Furie, Eric F Morand, et al.
Advances in Therapy|September 8, 2025
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus ErythematosusCristina Arriens, Eric F Morand, Anca D Askanase, et al.
Scientific Reports|October 30, 2019
Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosusSarah A Jones, Stuart Cantsilieris, Huapeng Fan, et al.
Nucleic Acids Research|June 12, 2012
A miR-19 regulon that controls NF-κB signalingMichael P Gantier, H James Stunden, Claire E McCoy, et al.
Pageof 23